Phase One Clinical Trial Set to Begin in Early 2016

Keystone Nano, a company located in the incubator in Innovation Park, received a $2 million grant from The National Cancer Institute (NCI) to support the phase one clinical trial of Ceramide NanoLiposome (CNL), a potential cancer therapy.

Most current chemotherapy treatments have little to no selectivity for cancerous tissue, resulting in damage to healthy tissues. That, in turn, can lead to uncomfortable and intolerable toxic side effects that limit the dosage of treatments a patient can have.

Keystone’s Ceramide NanoLiposome (CNL) has a unique mechanism that allows it to selectively kill cancer cells without negatively affecting ordinary cells. It has already shown positive effects in multiple animal models of cancer including human liver cancer, breast cancer, melanoma, pancreatic cancer and leukemia.

The Small Business Investigational Research (SBIR) Grant had many worthy applicants, and Keystone Nano is excited to take the next step in the development of this potential treatment.

The clinical trial will help Keystone learn more about the therapy’s effect in patients and is expected to begin in early 2016.

Click here for the full story.